What Happens If You Put Testosterone Gel on Your Scrotum?

Applying testosterone gel to scrotal skin dramatically increases how quickly and efficiently the hormone enters your bloodstream compared to putting it on your shoulder, abdomen, or thigh. Scrotal skin is unusually thin and highly permeable to steroid hormones, which means a much smaller dose can produce the same blood testosterone levels you would get from a larger amount applied elsewhere. That efficiency comes with trade-offs, though, including a sharp rise in a potent testosterone byproduct called DHT, real risks of transferring the hormone to sexual partners, and a set of practical concerns that explain why most commercial testosterone gels are still labeled for non-scrotal skin.

Why Scrotal Skin Absorbs So Much More

The skin on the scrotum is structurally different from skin almost anywhere else on your body. It is thinner, has less of the tough outer barrier layer that slows absorption on sites like the upper arm, and is rich in blood vessels sitting close to the surface. These features combine to make scrotal skin far more permeable to steroid hormones than typical application sites.¹ In practical terms, that means you can use a fraction of the dose and still reach the same therapeutic testosterone levels.

A pharmacokinetic study directly measured what happens when testosterone cream is applied to scrotal skin. Using a 25 mg dose, testosterone reached peak blood levels in roughly two to three hours and maintained physiological (normal-range) concentrations for about 16 hours. That is a fast onset by transdermal standards, and it happened with a dose substantially smaller than what non-scrotal gels require.¹ For comparison, standard non-scrotal testosterone gels are typically dosed at 50 to 100 mg per application to achieve similar blood levels.

A separate multicentre trial compared scrotal application of a hydroalcoholic gel (just 1 gram applied to the scrotum) against 5 grams of the same gel applied to non-scrotal skin and two daily testosterone patches. The scrotal gel group and the patch group achieved equivalent testosterone and free testosterone levels over 24 weeks, while the non-scrotal gel group at the higher dose was actually superior to both.² The key takeaway is that scrotal application works, and it works with far less product, though the best testosterone levels in that trial came from a larger non-scrotal dose.

The DHT Spike

This is the part of the scrotal application story that gets the most clinical attention. When testosterone passes through scrotal skin, much of it is converted into dihydrotestosterone (DHT) by an enzyme called 5-alpha reductase, which is especially active in genital skin. DHT is a more potent androgen than testosterone itself, and scrotal application produces noticeably higher DHT levels than other routes.

In the pharmacokinetic study mentioned above, serum DHT rose in a time-dependent fashion, reaching a peak concentration of about 1.2 ng/mL roughly five hours after application. That peak lagged behind the testosterone peak by about two hours, consistent with the testosterone being absorbed first and then locally converted.¹ The same study found no significant changes in serum estradiol, which is one potential upside: scrotal application may push hormone metabolism toward DHT rather than estrogen.

Whether that DHT elevation matters clinically is a question researchers have wrestled with since the 1990s, when the first scrotal testosterone patch (Testoderm) was on the market. Historical data from that era confirmed the DHT increase was a consistent feature of scrotal delivery.³ DHT is implicated in androgenetic hair loss and, historically, in prostate growth, so elevated levels have always raised the question of whether scrotal application carries extra long-term risk in those areas. But the clinical trials that tracked prostate size and PSA during scrotal testosterone use did not find alarming prostate changes compared to other delivery routes. The evidence is thinner than anyone would like, though, because most modern testosterone replacement trials use non-scrotal gels or injections.

What Elevated DHT Can Actually Do to You

DHT is the hormone primarily responsible for male pattern baldness. If you are genetically predisposed to hair loss, chronically elevated DHT levels could accelerate the process. This is why some men on testosterone replacement therapy (regardless of application site) notice thinning at the temples or crown. Scrotal application pushes DHT higher than other routes, so the concern is amplified.

DHT also drives sebaceous gland activity, which means oilier skin and a higher likelihood of acne. Men who already deal with body acne or cystic acne on testosterone therapy may find that scrotal application worsens the problem. On the other hand, DHT plays a role in libido and erectile function, and some men who switch to scrotal application report subjective improvements in sexual function that they attribute to the higher DHT. That benefit is anecdotal and hard to separate from the placebo effect of trying a new approach, but it is one of the reasons the method has gained popularity in online TRT communities.

As for the prostate, there is a broader picture worth understanding. Testosterone treatment in general raises PSA levels. In a study of severely hypogonadal men, median PSA went from 0.30 ng/mL at baseline to 0.95 ng/mL in the first one to three months and to 1.20 ng/mL by six to eighteen months. About 13 percent of the men exceeded a PSA of 4.0 ng/mL (the threshold that often triggers further evaluation) within that time frame.⁴ That study looked at testosterone treatment broadly, not scrotal application specifically, but the finding matters because any route that produces higher androgen levels (as scrotal does with DHT) could theoretically amplify this trend. The Testoderm-era data did not show prostate size increasing to above normal, and PSA did not rise to levels requiring concern in most patients, but regular monitoring remains standard practice for anyone on testosterone therapy.³

Transfer Risk to Partners

One of the more serious and underappreciated dangers of scrotal testosterone application is what happens during intimate contact. A case series documented the consequences for female partners of men using topical testosterone on the scrotum: the women experienced extraordinarily elevated testosterone levels from direct intravaginal absorption during sexual intercourse.⁵ The scrotal skin may absorb the gel quickly, but residue can persist on the surface, and the vaginal mucosa is extremely efficient at absorbing steroids.

Secondary transfer is a known risk with all topical testosterone products, which is why labels for standard gels instruct you to wash your hands after application and cover the site with clothing. But scrotal application introduces a transfer pathway that hand-washing and a shirt cannot address. The testosterone is sitting on a body part that comes into direct mucosal contact during sex. For female partners, supraphysiological testosterone levels can cause acne, deepened voice, menstrual irregularities, and virilizing symptoms that may not fully reverse. For anyone considering scrotal application, a meaningful waiting period between application and sexual contact, combined with thorough washing, is a non-negotiable safety step.

Why Most Gels Are Not Labeled for Scrotal Use

Despite the pharmacokinetic advantages, mainstream testosterone gel products like AndroGel and Testim are labeled for application to the shoulders, upper arms, or abdomen. That is partly a regulatory artifact. The clinical trials submitted for FDA approval tested those specific sites, and the approval applies only where the data supports it. Manufacturers would need to run additional pharmacokinetic and safety trials with scrotal application to get an updated label, and there is not much commercial incentive to do so when the products already sell well for their approved sites.

There is also a practical issue of dose control. Because scrotal skin absorbs so efficiently, the standard dose in a commercial gel packet could deliver far more testosterone than intended when applied to the scrotum. A man who squeezes out his usual 50 mg pump of AndroGel and puts it on his scrotum is not getting the same blood levels he would from applying it to his shoulder. He is getting substantially more, potentially pushing into supraphysiological territory. Without dose adjustments and monitoring tailored to scrotal absorption, this is a recipe for side effects.

Compounding pharmacies have stepped into this gap. Some clinicians who prescribe scrotal testosterone work with compounders to create low-dose creams specifically formulated for scrotal application, typically in the range of 10 to 25 mg per dose rather than the 50 to 100 mg in standard products. The pharmacokinetic evidence supports this approach: a 25 mg scrotal dose maintained physiological testosterone levels for 16 hours in a controlled study.¹ But compounded preparations are not subject to the same quality controls as FDA-approved products, and potency can vary between batches, which adds another layer of uncertainty.

Scrotal Application and Fertility

A common misconception is that applying testosterone locally to the scrotum, in close proximity to the testes, might be less harmful to sperm production than injecting it into muscle. The reality is the opposite of what intuition suggests. Exogenous testosterone suppresses sperm production regardless of how or where it enters the body, because the suppression happens at the level of the brain, not the testes themselves.

When external testosterone raises blood levels, the pituitary gland detects the surplus and dials back its signals (LH and FSH) to the testes. Without those signals, the testes stop producing their own testosterone and greatly reduce or halt sperm production. Switching from injectable testosterone to a topical form applied to the scrotum does not protect against this effect.⁶ The route of administration is irrelevant to the hormonal feedback loop that governs fertility. If you are trying to conceive or want to preserve fertility, any form of exogenous testosterone is counterproductive, and scrotal application is no exception.

Tolerability Compared to Patches and Non-Scrotal Gels

One genuine advantage of scrotal gel application is comfort. The old scrotal testosterone patches (Testoderm) were notorious for adhesion problems and skin reactions. The adhesive had to stick to scrotal skin, which is mobile and often moist, and many men found the patches uncomfortable, irritating, or unreliable. Men with smaller scrotal surface area sometimes could not get the patch to adhere properly at all.³ Non-scrotal patches (Androderm) reduced the adhesion headache but introduced their own issue: skin irritation at the application site was common enough to force some patients to discontinue.

In the multicentre trial comparing scrotal gel, non-scrotal gel, and patches over 24 weeks, tolerability was much better in both gel groups than in the patch group. Sexual function, mood, and quality-of-life questionnaires did not differ between the three treatment arms, suggesting that once testosterone levels are in range, the delivery method does not change the subjective experience much.² The gel is easy to apply, absorbs quickly, and does not leave visible residue on scrotal skin the way it can on the shoulders or chest. For men who dislike the stickiness of patches or the visible gel residue on their arms, scrotal application can feel like a more discreet option.

What About Blood Counts

Testosterone replacement, by any route, can stimulate red blood cell production. When this goes too far, it leads to erythrocytosis, a condition where your blood becomes thicker than normal. Thickened blood raises the risk of blood clots, stroke, and cardiovascular events. This is one of the most important safety parameters your doctor monitors through periodic blood work, typically checking your hematocrit level.

Whether scrotal application raises hematocrit more or less than other routes has not been well studied in head-to-head comparisons. The multicentre trial that compared scrotal gel, non-scrotal gel, and patches did not report specific hematological findings for each group. In theory, because scrotal application produces sharper testosterone peaks rather than the steady-state levels of some other delivery methods, the periodic spikes might stimulate erythropoiesis differently. But that is speculation, not established evidence. For now, the standard advice applies: if you are on any form of testosterone, get your blood counts checked regularly, and do not assume scrotal application is either safer or riskier on this front.

The Estradiol Question

Some men are drawn to scrotal application specifically because they have heard it produces less estrogen conversion. There is a kernel of truth to this. The pharmacokinetic data showed no significant changes in serum estradiol after scrotal testosterone cream application.¹ The likely explanation is straightforward: scrotal skin is rich in 5-alpha reductase (the enzyme that converts testosterone to DHT) but has less aromatase activity (the enzyme that converts testosterone to estradiol). So the testosterone that passes through scrotal skin gets shunted preferentially toward DHT rather than estrogen.

For men who struggle with estrogen-related side effects on standard testosterone therapy, such as water retention, breast tenderness, or mood changes, this metabolic profile can look attractive. Some clinicians prescribe scrotal testosterone cream for this reason, particularly in men who would otherwise need an aromatase inhibitor to keep estradiol in check. The caveat is that the DHT trade-off comes along for the ride. You may reduce estrogen-related problems while increasing DHT-related ones. It is not a free lunch so much as a different set of trade-offs, and which set of side effects matters more depends on the individual.

Skin Reactions and Local Side Effects

The pharmacokinetic study of scrotal testosterone cream reported that the treatment was well tolerated locally.¹ Scrotal skin, despite being thin, generally handles topical formulations better than people expect. The alcohol-based gels (like those used for non-scrotal sites) can sting or cause irritation on the scrotum due to its sensitivity, which is one reason compounded creams with non-alcoholic bases are often preferred for this application site. If you use a standard hydroalcoholic gel on the scrotum, expect a burning or stinging sensation that may or may not diminish with repeated use.

The old scrotal patches caused skin reactions frequently enough that it was listed as a notable limitation. Redness, itching, and contact dermatitis at the adhesive site were common complaints.³ Gels and creams largely eliminate the adhesive problem, but any topical product applied daily to the same area can cause cumulative irritation over time. Men who notice persistent redness, itching, or changes in scrotal skin texture should flag these with their prescriber.

Historical Context and the Testoderm Era

Scrotal testosterone delivery is not a new idea cooked up by internet biohackers. The first transdermal testosterone product approved in the United States was Testoderm, a patch designed specifically for scrotal application, introduced in the early 1990s. It worked well pharmacologically: most patients achieved normal testosterone levels with a circadian rhythm that mimicked natural production, and clinical responses in mood, energy, and sexual function were comparable to intramuscular injections.³

Testoderm was eventually eclipsed by non-scrotal options, not because it did not work, but because of the practical hassles. The scrotal area had to be shaved for the patch to adhere, the patch sometimes fell off during exercise or sweating, and the entire concept struck many patients (and their partners) as awkward. When non-scrotal patches and then gels entered the market, patients and clinicians migrated toward the more convenient options. The pharmacological case for scrotal delivery never weakened, but the practical and social barriers proved decisive. The current wave of interest in scrotal testosterone cream, driven largely by online TRT communities and prescribers at men’s health clinics, is essentially a rediscovery of a principle that endocrinologists documented three decades ago, now with a more user-friendly cream format replacing the old patches.

1
PubMed. Pharmacokinetics of testosterone cream applied to scrotal skin
2
Oxford Academic / European Journal of Endocrinology. Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial
3
Endocrinologist. Transdermal testosterone delivery systems
4
Journal of the Endocrine Society. Prostate-Specific Antigen Concentrations in Response to Testosterone Treatment of Severely Hypogonadal Men
5
PubMed Central. The Unintended Consequences Of Applying Topical Testosterone Directly To The Scrotum
6
Translational Andrology and Urology. Exogenous testosterone: a preventable cause of male infertility